Mass-sensing BioCD Protein Array towards Clinical Application: Prostate Specific Antigen Detection in Patient Sera

TL;DR

This study demonstrates the use of a mass-sensing BioCD biosensor array for detecting prostate specific antigen in patient serum samples without labels, achieving high sensitivity suitable for clinical applications.

Contribution

The paper introduces a BioCD-based mass biosensor array capable of detecting PSA in serum with high sensitivity, demonstrating its potential for clinical diagnostics.

Findings

Detection limit of 4 ng/ml in serum

Successful measurement of PSA in patient sera

Operates without fluorophores or enzyme labels

Abstract

Mass-sensing biosensor arrays for protein detection require no fluorophores or enzyme labels. However, few mass biosensor protein arrays have demonstrated successful application in high background samples, such as serum. In this paper, we test the BioCD as a mass biosensor based on optical interferometry of antibodies covalently attached through Schiff-base reduction. We use the BioCD to detect prostate specific antigen (PSA, a biomarker of prostate cancer) in patient sera in a 96-well anti-PSA microarray. We have attained a 4 ng/ml detection limit in full serum and have measured PSA concentrations in three patient sera.